Clinical trial

Characteristics of Sexual Dysfunction in Patients With Lung Cancer

Name
GECP 23/01_LUDICAS
Description
The general objective of this observational study is identify and describe the type, frequency, and severity of sexual dysfunction in patients with lung cancer and generate strategies for clinical management and oncological follow-up directed and based on the specific findings in this population. The recruitment will be carried out from July 2023 and will be carried out until December 2023, the analysis of the information will be carried out from January to March 2024.
Trial arms
Trial start
2023-07-13
Estimated PCD
2024-02-29
Trial end
2024-02-29
Status
Completed
Treatment
Systemic oncological treatment
Oncological systemic treatment for at least 3 months or being in oncological follow-up after having received systemic treatment for a minimum of 3 months
Arms:
Observational Study Group
Other names:
chemotherapy, radiotherapy
Size
553
Primary endpoint
Number of Participants with different type, frequency and severity of sexual dysfunction
From inclusion up to 3 months
Eligibility criteria
Inclusion Criteria: * Age greater than or equal to 18 years and less than or equal to 70 years. * Diagnosis of lung cancer stages IB to IV. * Having received systemic oncological treatment for at least 3 months or being in oncological follow-up after having received systemic treatment for a minimum of 3 months with stable tumor disease or partial or complete response in images. * ECOG ≤ 2 Exclusion Criteria: * Patients with comorbidities (renal failure, cardiovascular diseases or similar) not controlled with corresponding medical management. * Individuals with physical disability or cognitive impairment that prevents them from completing the electronic data collection form.
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_ONLY', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 553, 'type': 'ACTUAL'}}
Updated at
2024-05-06

1 organization

1 product

2 indications

Organization
Fundación GECP
Indication
lung cancer